

VPA10996/207/001

Nuflor Minidose 450 mg/ml solution for injection for cattle

Variation	Summary	Date
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	11/03/24
Vet - G.I.Z	VRA-S - Vet - G.I.Z - Change(s) in the SPC, labelling or package leaflet intended to implement the outcome of a procedure - Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet intended to implement the outcome of a Union interest referral procedure according to Article 83 of Regulation (EU) 2019/6 . Other changes under this code level, e.g. variations outlined in section 6 and 7 of this guidance	11/03/24
Vet - F.II.b.2 b) z.	VRA-R - Vet - F.II.b.2 b) z. - b) Replacement or addition of a manufacturer responsible for importation and/or batch release z. Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.b.2 b) z. Quality Changes - Finished Product -Manufacture - Change to importer, batch release arrangements and quality control testing of the finished product - Replacement or addition of a manufacturer responsible for importation and/or batch release - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	03/02/23
Vet - F.II.c.2 b)	VRA-R - Vet - F.II.c.2 b) - b) Other changes to a test procedure (including replacement or addition) - F.II.c.2 b) Quality Changes - Finished Product -Control of excipients-Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition)	03/02/23
Vet - F.II.b.3 a)	VRA-R - Vet - F.II.b.3 a) - a) Minor change in the manufacturing process - F.II.b.3 a) Quality Changes - Finished Product -Manufacture - Change in the manufacturing process of the finished product, including an intermediate used in the	03/02/23

	manufacture of the finished product - Minor change in the manufacturing process	
Vet - F.II.b.1 z)	VRA-R - Vet - F.II.b.1 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.b.1 z) Quality Changes - Finished Product -Manufacture - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	03/02/23
Vet - F.II.b.1 d)	VRA-R - Vet - F.II.b.1 d) - d) Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile veterianry medicinal products (including those that are aseptically manufactured) excluding biological/ immunological veterinary medicinal products - F.II.b.1 d) Quality Changes - Finished Product -Manufacture - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile veterianry medicinal products (including those that are aseptically manufactured) excluding biological/ immunological veterinary medicinal products	03/02/23
Vet - B11 b)	VNRA - Vet - B11 b) - b) Tightening of specification limits of an active substance, starting material, intermediate or reagent used in the manufacturing process of the active substance - B11 b) Changes to the quality part of the dossier: Change in the specification parameters or limits of an active substance, starting material, intermediate or reagent used in the manufacturing process of the active substance or of the immediate packaging of the active substance — tightening of specification limits of an active substance, starting material, intermediate or reagent used in the manufacturing process of the active substance	20/01/23